Archive for July 13th, 2006

Viet Nam joins Madrid!

Thursday, July 13th, 2006

Viet Nam joined the Madrid Protocol on July 11, 2006.To register trademarks in member countries of the Madrid Protocol, owners will now just need to file a single application to the World Intellectual Property Organisation through the Department of Intellectual Property at the Ministry of Science and Technology.

Accession to the Madrid Protocol will help businesses reduce registration costs, which can range from US$1,500 to $2000 in the US and up to $2,500 in Japan.

Under the Madrid Agreement, a single $1,500 registration will protect a trademark in 46 participating countries, including the European Union (EU), the UK, the US, Japan, Singapore and the South Korea, all of which are important markets for Vietnamese companies. The waiting period for registration is 1-2 years, half the typical wait for single nation registrations.

According to the article, “Improving intellectual property protection would promote investment and trade for both local and international businesses operating in Viet Nam, he said, adding a 1.5 million euro project to apply the ECAP II programme would soon be underway.”

Related links:

WIPO/Madrid Protocol

Madrid Protocol in the U.S.

FDA Approves Single-dose “Cocktail” for HIV Treatment

Thursday, July 13th, 2006

Yesterday, the FDA a new combination drug for the treatment of HIV/AIDS. The new drug is called ATRIPLA and is a combination of Bristol-Myers Squibb’s SUSTIVA (efavirenz) and Gilead Science’s VIREAD (tenofovir) and EMTRIVA (emtricitabine). Currently, VIREAD (tenofovir) and EMTRIVA (emtricitabine) are available in a single pill as TRUVADA.

The pill will be just as expensive as Truvada and Sustiva when purchased separately: The wholesale price will be $1,150 for a 30-day supply. Switching to the combo pill would require insured patients to make just one, rather than two, co-payments, saving some money.

However, it is hoped that being able to take three treatments in one will markedly improve patient compliance with their treatment regimens.